Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Mueller

Showing results (171-180 of 180) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 180 results.
Nature Communications|July 1, 2021
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2Donata Hoffmann, Björn Corleis, Susanne Rauch, et al.
Wiener Klinische Wochenschrift|August 11, 2021
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trialPeter G Kremsner, Philipp Mann, Arne Kroidl, et al.
Journal of Proteomics|December 15, 2012
Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stressAnja Wilmes, Alice Limonciel, Lydia Aschauer, et al.
Human Vaccines & Immunotherapeutics|October 18, 2024
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation studyBrandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, et al.
Nature|November 18, 2021
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccineMakda S Gebre, Susanne Rauch, Nicole Roth, et al.
The New England Journal of Medicine|June 13, 2017
Health Effects of Overweight and Obesity in 195 Countries over 25 Years, Ashkan Afshin, Mohammad H Forouzanfar, et al.
Lancet (London, England)|May 7, 2014
Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013Haidong Wang, Chelsea A Liddell, Matthew M Coates, et al.
Lancet (London, England)|May 7, 2014
Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013Nicholas J Kassebaum, Amelia Bertozzi-Villa, Megan S Coggeshall, et al.
Lancet (London, England)|September 1, 2015
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition, Christopher J L Murray, Ryan M Barber, et al.
Lancet (London, England)|September 15, 2015
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013, Mohammad H Forouzanfar, Lily Alexander, et al.
Pageof 18

Showing results (171-180 of 180) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Nature Communications|July 1, 2021
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2Donata Hoffmann, Björn Corleis, Susanne Rauch, et al.
Wiener Klinische Wochenschrift|August 11, 2021
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trialPeter G Kremsner, Philipp Mann, Arne Kroidl, et al.
Journal of Proteomics|December 15, 2012
Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stressAnja Wilmes, Alice Limonciel, Lydia Aschauer, et al.
Human Vaccines & Immunotherapeutics|October 18, 2024
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation studyBrandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, et al.
Nature|November 18, 2021
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccineMakda S Gebre, Susanne Rauch, Nicole Roth, et al.
The New England Journal of Medicine|June 13, 2017
Health Effects of Overweight and Obesity in 195 Countries over 25 Years, Ashkan Afshin, Mohammad H Forouzanfar, et al.
Lancet (London, England)|May 7, 2014
Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013Haidong Wang, Chelsea A Liddell, Matthew M Coates, et al.
Lancet (London, England)|May 7, 2014
Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013Nicholas J Kassebaum, Amelia Bertozzi-Villa, Megan S Coggeshall, et al.
Lancet (London, England)|September 1, 2015
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition, Christopher J L Murray, Ryan M Barber, et al.
Lancet (London, England)|September 15, 2015
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013, Mohammad H Forouzanfar, Lily Alexander, et al.
Pageof 18